A recently developed ATM inhibitor enhances radiation-induced T1IFN, leading to both innate and subsequent adaptive anti-tumoral immune responses and sensitization of immunotherapy-resistant pancreatic cancer. Here, ATM is linked to familial pancreatic carcinoma.